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Sir,
The treatment of advanced hepatocellular carcinoma (HCC) in
patients no longer eligible for surgical, percutaneous or transarter-
ial therapies is dismal. Chemotherapy, anti-estrogens or anti-
androgens, retinol derivatives or stem cell factors have been tested
with poor results, and we eagerly wait for the results of ‘biologic’
treatments, such as sorafenib.
Since the first enthusiastic report on Octreotide (Kouroumalis
et al, 1998), in which HCC patients were characterized by
somatostatin receptor expression and survival was significantly
longer in the octreotide-treated arm, several papers have been
published that almost constantly failed in confirming these
preliminary data (Yuen et al, 2002; Slijkhuis et al, 2005).
The recent papers by Cebon in the British Journal of Cancer
(Cebon et al, 2006) and by Becker in Hepatology (Becker et al,
2007) are a kind of obituary to the use of the drug in HCC and will
probably lead to a definite stop to any attempt to treat HCC with
octreotide, which is also an expensive drug. Indeed, in the two
studies not only had the drug no impact on survival, even the
quality of life was absolutely unaffected by the treatment. In the
former study, only about 50% of the patients had a positive
Octreoscan, while in the latter, the receptor status was not assessed.
One could therefore say that the chances for the drug to work in
receptor-negative patients are quite small. In previous papers, the
percentage of receptor-positive patients was not defined (Treiber
et al, 2006) or showed wide variability (Reynaert et al, 2004), even
in relation to the type of receptor tested (Blaker et al, 2004).
In Italy, the rules for prescription require a positive Octreoscan as
mandatory and we therefore recruited 25 consecutive patients
diagnosed in the last 6 months, who had advanced stage HCC,
according to the American Association for the Study of Liver Disease
(AASLD) (Bruix and Sherman, 2005) (Table 1) and performed the
imaging technique. In contrast with that found by Cebon, only 2/25
(8%) patients tested positive. Both had multifocal disease, hepatatis
C virus-related aetiology, one had a large size HCC (Figure 1) and
very high a-fetoprotein levels (245.000mgdl
1). One of the two
refused the treatment. The second soon became intolerant,
developed diarrhoea and nausea, interrupted the treatment after 2
months and died of upper gastrointestinal bleeding at 4 months.
As in our experience, the somatostatin receptor (SSTR)
expression in HCC is independent of tumour stage, differentiation,
underlying liver disease and/or histological type (Blaker et al,
2004) and none of these parameters is therefore predictive
of somatostatin analogue treatment response. As said, selection
of HCC patients with more sensitive methods of SSTR expression
(reverse transcription – polymerase chain reaction or immuno-
histochemistry, among which a high correlation is present),
have not and will not change the picture. The clinical availability
of new synthetic SSTRs pan-inhibitors such as SOM230 or
BIM-23A779 (high affinity for SSTR1, SSTR2, SSTR3, SSTR5),
could define whether the low or absent of in vivo effect on
proliferation and apoptosis of the available analogues is related to
the incapacity to stimulate a specific SSTR subtype or to a
generally modest antiproliferative activity of these receptors
(Reynaert et al, 2004).
Table 1 Clinical features of the HCC patients recruited
Variables N (total 25) %
Gender
Male 20 80
Female 5 20
Aetiology disease
HBV 1 4
HCV 16 65
Alcohol (+/ viruses) 8 31
AFP
o20ngdl
1 83 1
20–200mgl
1 10 42
4200mgl
1 72 7
Lesion number
1–3 7 29
431 8 7 1
Tumour size
o5cm 19 74
45cm 6 26
Edmonson’s grade of differentiation(in patients biopsied)
Well differentiated 5 71
Moderately differentiated 2 29
Abbreviations: AFP, a-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus.
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Figure 1 Octreotide Scintigraphy showing pathologic uptake in right liver lobe and normal uptake in spleen.
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